Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

Background

Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their economic implications.

Methods

Each drug's short-term efficacy was estimated based on independent Cochrane reviews of the clinical trials. Long-term clinical and economic outcomes were estimated using the Assessment of Health Economics in Alzheimer's Disease (AHEAD) model.

Results

While all treatments reduced the need for full-time care, only galantamine and donepezil 10 mg reduced the overall management costs of AD patients. The somewhat greater cognitive effect provided over six months by galantamine leads to the longest estimated delay before full-time care is required and, consequently to lower overall costs, with savings estimated at between $323 and $4,246.

Conclusion

Although there is uncertainty in estimated results, the best information currently available suggests that the first choice for treatment of AD should be galantamine. These results should be interpreted with caution, however, as results are not based on direct comparisons among the drugs and the differences emerging from meta-analyses of the trials are relatively small.

The number of Canadians with Alzheimer's disease (AD) is expected to rise to over half a million by 2031 [1], and the costs of caring for these patients have been shown to be heavily dependent on disease severity [2, 3], with a recent estimate of $9,451 (1996 Canadian dollars) per year for patients with mild AD to $36,794 per year for patients with severe AD [3].

Although the adoption of cholinesterase inhibitors for the treatment of AD has not met with unconditional endorsement in Canada [4, 5], this was the only class of anti-dementia drugs recommended by the Canadian Consensus Conference on Dementia [6] and is becoming the standard of care. It is hoped that the short-term benefits observed in clinical trials lasting a few months [7–9] will translate to slower decline over the subsequent years.

No studies have yet fully documented the long-term economic implications of treatment with these drugs, but four [10–13] have estimated what they might be in Canada using models of the course of the illness. Similar analyses have also been carried out for other countries [14–21]. Although each of the Canadian analyses predicted delayed disease progression and associated savings, the lack of a common methodology and contrasts with other active treatments mean that the results are not directly comparable and, thus, do not help in making choices among the drugs.

To inform therapeutic decisions, we undertook a comparison of the three cholinesterase inhibitors approved for use in Canada: donepezil, rivastigmine and galantamine. We sought to remove extraneous effects due to disparate modeling approaches by using a common, published and validated, analytic framework: the Assessment of Health Economics in Alzheimer's Disease (AHEAD) model [22]. To ensure balanced estimates of the efficacy of these drugs, particularly given our source of funding, we based our calculations on the independent reviews published by the Cochrane Collaboration [23–25].

The AHEAD Model

The AHEAD model simulates the course of AD according to the patient's characteristics at a given point in time [13, 22]. This is done by forecasting the time until each patient with AD requires full-time care (FTC) – the consistent requirement for a significant amount of caregiving and supervision for the greater part of the day, regardless of the locus of care and who the caregiver is. These forecasts are derived by estimating the failure-time curves that result from the corresponding time-dependent hazards. The hazards are calculated using equations that depend on the presence of extrapyramidal symptoms (EPS), the presence of psychotic symptoms, age at onset, duration of illness and cognitive status. The model also forecasts survival, which depends on sex, EPS, duration of illness and cognitive status. The required equations were derived from published long-term follow up data of patients with AD [26].

The model considers four states: 1) not yet requiring FTC (pre-FTC), 2) requiring FTC but still living in the community (FTC community), 3) requiring FTC and institutionalized (FTC institution), or 4) dead. The model uses individual patient data as inputs into the predictive equations, and the individual results are then aggregated into an overall forecast for the entire cohort. Comparisons between treatment scenarios are achieved by re-computing the failure-time curves for the same patients under each treatment scenario.

The cognitive portion of the Alzheimer Disease Assessment Scale (ADAS-cog) [27] is used as the measure of cognition in this model as cognitive outcomes of trials are typically reported using this measure. Cognitive status after six months (C₆) in the absence of pharmacologic treatment is forecast using a regression equation based on baseline cognitive status (C₀). The equation, derived from patient-level data on untreated participants in three clinical trials [28–30] was C₆ = -0.54+1.10 C₀ (the 95% confidence intervals for the coefficients were -1.94 to 0.97 for the intercept term, and 1.05 to 1.15 for the slope term). An increase in the score reflects deterioration in cognitive functioning.

Along with the duration of FTC and economic outcomes, the model calculates quality adjusted life years (QALY) remaining by assigning quality "weights" to each state. Values of 0.603 for pre-FTC, 0.338 for FTC regardless of location of care, and 0 for death were derived from published data [31]. A single value was used for FTC as the study on which quality weights were based found that setting of care did not have an independent effect on outcomes [31].

If one treatment is estimated to increase health benefits but also the costs relative to the next most effective treatment, the model calculates the incremental cost-effectiveness ratio in terms of the net cost per QALY gained (both discounted). Pair-wise comparisons, even for treatments otherwise dominated, are also reported here since these may be relevant in settings where the dominant treatment cannot be used.

Results are forecast over ten years from the start of treatment because by that time all survivors require FTC. A rate of 3% per annum was used to discount costs and health benefits occurring after year one.

Population for Analyses

To provide a common population of patients for these analyses, the clinical and demographic characteristics of participants in a recent clinical trial [30] were used. Among these 918 patients, who should be broadly representative of those for whom the drugs are indicated, 64.9% were female and the mean age was 77.2 years. ADAS-Cog scores ranged from 10 to 62, with the mean ADAS-cog score at baseline being 28.9 and the first and third quartiles of the distribution being 21 and 36, respectively. Psychotic symptoms were exhibited in 32.4% of the patient population, 7.5% had EPS, 8.9% had early onset of disease, and the mean duration of illness was just over four years. In the absence of pharmacologic treatment, it was estimated that after six months, the average ADAS-cog score would deteriorate to 31.3.

Treatment Efficacy

Computations for each treatment were based on the cognitive effects reported in the Cochrane reviews – formal meta-analyses of the randomized clinical trials assessing efficacy and safety of these drugs. For each drug and dose, the reviews reported point estimates and 95% confidence intervals (CI) for the weighted difference in mean cognitive change comparing the treatment to placebo using intention-to-treat analysis with last observation carried forward (LOCF) methods used for patients dropping out of the trial (Table 1). While it is possible that the LOCF method may slightly overestimate the cognitive effects of treatment if withdrawals from the trial are higher with treatment than without (as patients cognition, on average, should decline between the time of withdrawal and the end of the study), these were the only data available for all three active treatments and the same methods were used for all.

These estimates were used to determine the change in cognition expected with each treatment and dose over six months for each patient in the model population. Two approaches were taken to make these predictions. For the main analyses, the most direct approach was used: the Cochrane estimated mean difference from placebo (ΔC) was applied to the intercept term in the regression equation that describes progression without treatment: C₆ = (-0.54+ ΔC) + 1.10 C₀. This implies that treatment has a constant absolute effect on cognition, regardless of baseline ADAS-cog – thus termed the 'constant effect' analysis.

To consider possible dependency of the treatment effect on the baseline disease severity [32, 33], a second, 'variable effect", approach was used in sensitivity analyses. For this approach, a term was added to the regression equation reflecting the interaction between treatment (T) and baseline ADAS-cog score: C₆ = -0.54+1.10 C₀+ β·T·C₀. The coefficient β was estimated for each treatment by solving the equation at the mean baseline ADAS-cog scores reported for each treatment arm in the trials [28–30], [34–36]: β = ΔC/ (Table 1).

In both the constant and variable effect analyses, the treatment effect was applied only to patients who were predicted to complete the first six months of therapy. For those predicted to withdraw from therapy, the rates of cognitive change expected without treatment were applied. The likelihood of completing the first six months of treatment was predicted for each patient by adjusting the base withdrawal rate incorporated in AHEAD according to a treatment-specific factor derived from the Cochrane reviews by calculating the ratio of treatment to placebo withdrawals (Table 1). For example, if treatment were associated with a relative risk of withdrawing equal to 2, and the base withdrawal risk for a patient were 10%, then with treatment, the withdrawal risk would be 20% (2 × 10%). The overall base withdrawal rate in AHEAD was 16%.

Although there is evidence that these drugs may have an impact on psychotic symptoms [37], this aspect was not included in these analyses because those data were not reported in the Cochrane reviews for all treatments.

Evidence that treatment affects survival is not yet available so mortality was assumed to be equal for all therapeutic options. This equivalence was ensured by calculating mortality with all three treatments using the ADAS-cog scores had the patients remained untreated.

Costs

Costs are reported in 2001 Canadian dollars and are determined from the perspective somewhat broader than that of a comprehensive payer. For example, informal costs such as in-home personal care were included. Costs were estimated based primarily on resource use data from the clinical assessment portion of a follow-up survey of the Canadian Study of Health and Aging [38] and unit costs from the province of Quebec using methods described elsewhere [13]. The estimates were $432 per patient per month before FTC is required, $903 monthly for FTC in the community and $3,931 for a month of FTC in an institution. Based on published data, it is expected that that almost three-quarters (73.5%) of patients requiring FTC will be institutionalized [3, 13]. No event cost was assigned to the transition to FTC or to death. The daily cost of each cholinesterase inhibitor was set at $4.59. Daily treatment cost was independent of dose, reflecting current pricing practices for cholinesterase inhibitors in Canada. Patients predicted to discontinue treatment were assumed to consume three months of drug. It was conservatively assumed that to maintain the cognitive benefit obtained, all those who do not withdraw in the first six months, require continued treatment until FTC is needed. Once this happens, pharmacologic treatment was assumed to end for all patients. Treatment discontinuation prior to needing FTC was not considered, although one might expect that in addition to no longer incurring treatment costs, benefits attained through treatment prior to discontinuation may be lost over time.

Sensitivity Analyses

Sensitivity analyses were performed on key inputs and assumptions. To reflect the uncertainty in the relative cognitive effect of each treatment, univariate sensitivity analyses were run using the upper and lower 95% confidence interval bounds for each drug's treatment effect. Health utility and cost inputs were varied and a potential survival benefit based on the cognitive effect was explored. Sensitivity analyses were also conducted assuming lower discontinuation rates, as the Cochrane reviews present evidence of modified dose-escalation regimens for each of the three therapies leading to significantly fewer drop-outs over the trial periods. Finally, all analyses were rerun using discount rates of 0%, 5% and 10%.

Apart from univariate analyses of each factor, multivariate probabilistic analyses were also carried out. The ranges over which each factor was changed in the multivariate analyses are displayed in Table 2.

With no pharmacologic treatment, the patients modeled are expected to survive, on average, an additional 60.3 months and to require FTC after an estimated 38.4 months. The average total cost of caring for these patients over the modeling period is $84,869 ($76,806 discounted).

Main Analysis

In the constant effect analysis, all treatments reduce the time FTC is required relative to no treatment, but only the higher dose of donepezil and both doses of galantamine reduce costs (Table 3). As these three treatment options also provide greater effects, they dominate the others (i.e., have greater health effects and lead to lower overall costs). Both doses of galantamine also dominate the higher dose of donepezil. The only cost-effectiveness scenario amongst active treatments exists with donepezil 5 mg, which has a superior health effect compared to rivastigmine 6–12 mg, but is more expensive, with incremental benefits attained at a cost of over $150,000 per QALY gained.

Sensitivity Analyses

Variable Effect

In the variable effect analyses, the most notable change is that the lower dose of galantamine was no longer dominant over donepezil 10 mg: now a nominal reduction of FTC need (0.1%) is obtained at an incremental cost of $3 per patient ($13,338 per QALY gained).

ADAS-Cog change

When the upper limits of the 95% confidence interval of the weighted difference in mean ADAS-cog change are used, the relative positions of the treatments do not change, but when the lower limits are used, the higher dose of donepezil dominates the lower one of galantamine. This results from the tighter interval around the donepezil estimate (Sensitivity analyses reported in the following sections were also carried out for the variable effect analyses. Results available from the authors.).

Treatment Withdrawal

The confidence intervals of the withdrawal adjustment factors for the lower doses of all three cholinesterase inhibitors included a value of one (i.e., withdrawal no different than with placebo), and there is some evidence that slower titration regimens might result in lower discontinuation rates even for the higher doses of these drugs. An analysis was therefore undertaken assuming that the withdrawal factor was one for all treatments. The only resulting change in position of the treatments was that higher dose rivastigmine dominated the lower dose of donepezil under these conditions.

Mortality

Although there is no evidence to indicate that cholinesterase inhibitors improve survival, if the cognitive benefits are allowed to translate to mortality reductions, all treatments are predicted to increase costs relative to no treatment because the additional survival incurs further costs. This does not affect, however, the position of the active treatments relative to one another.

FTC Costs

Changes in this parameter affect the results relative to no treatment, but not the comparisons among treatment options.

Health Utilities

Changes in health utility estimates of 25% in either direction had no appreciable impact on the comparisons among cholinesterase inhibitors.

Discount Rate

Alternative discount rates also had only a small influence on overall results, and did not influence the relative ranking of active treatments. For example, galantamine 24 mg resulted in net savings ranging from $249 to $4,705 if no discounting were applied. If a 10% rate were used, savings, although lower, were still attained in all cases, ranging from $201 to $3,414.

Multivariate Analysis

The results of the multivariate sensitivity analyses largely confirm the main ones. The higher dose of rivastigmine is always dominated by the higher dose of galantamine and nearly always (96.1%) by the lower dose of galantamine. The higher dose of donepezil is only dominated in about half the scenarios (55.6%) with respect to the lower dose of galantamine, and is dominated by the higher dose of galantamine most of the time (69.4%).

The results of these analyses, which incorporate the best currently available information, suggest that galantamine should be the first choice for treatment of patients with AD. Using the AHEAD model to extend independently published short-term efficacy estimates, galantamine is predicted to lead to a somewhat longer delay of the need for FTC and ultimately lower costs, thus dominating other treatment options. The second best choice appears to be donepezil.

These results need to be placed in context. To date, adequate direct comparisons of these drugs in clinical trials are lacking, and the Cochrane meta-analyses show relatively small differences among the treatments. Furthermore, it is impossible to ensure that differences among the study populations and trial protocols are fully accounted for, even in the variable effect analysis. It should also be kept in mind that treatment effects for all drugs were based on populations enrolled in clinical trials, which may not be representative of the AD population in Canada as a whole. Until long-term data become available for patients treated in the community, however, it is difficult to determine how much different the clinical effectiveness and tolerability of these drugs will be in actual practice relative to a clinical trial setting. Finally, long-term forecasts are made based on the results of trials that lasted only six months. Longer-term data are emerging [39–44], but these are even less comparative as most are open-label extensions of trials where most patients were switched to active treatment regardless of original assignment.

Despite these sources of uncertainty, the results are maintained over most sensitivity analyses. In the multivariate probabilistic sensitivity analyses, galantamine remained dominant in the vast majority of scenarios.

Other factors not taken into account in this analysis should also be considered as data become available. Of note, these analyses limit the effect of these drugs to cognition. There is growing evidence that aspects other than cognition may be improved by treatment [30, 37, 45, 46]. For example, in one double-blind placebo-controlled trial that measured behavioral symptoms [30], patients randomized to either galantamine 16 mg or 24 mg showed significant behavioral benefits over placebo-treated patients. This aspect of treatment was not included in the analysis, however, as appropriate data from randomized trials were not available for all three cholinesterase inhibitors under evaluation.

Caregiver burden has also not been considered [47–49] in this analysis. In Canada, the most recent estimate of caregiving costs places these at between $400 and $700 per patient, per month, depending on the stage of the disease [3] and the recent Canadian Consensus Conference on Dementia acknowledged the significant burden placed on caregivers of the demented elderly [6]. Data that would allow inclusion of caregiver burden and its attendant costs are beginning to appear. For example, the effects of galantamine on caregiver time were assessed in a 6-month randomized, placebo-controlled trial [50]. Caregivers of patients on galantamine spent less time supervising patients than caregivers of patients on placebo (by between 82 and 98 minutes per day). Caregivers of treated patients also spent between 38 and 61 minutes less per day assisting patients with activities of daily living. Inclusion of this aspect would add to the completeness of the analysis, and likely accentuate current results. As comparable data for donepezil and rivastigmine are currently lacking, however, a conservative approach was taken and caregiver burden was left out of the analysis.

It is also worth noting that individuals may respond to one drug better than another in ways not reflected by calculations based on the average effects in a population, such as those used in this analysis. Thus, treatment should be tailored to each patient, with careful monitoring of response and tolerability dictating the final treatment course.

With the number of Canadians with AD increasing and health care resources already stretched, it is becoming increasingly important to evaluate therapeutic alternatives for these patients to provide a rational basis for treatment decisions. These analyses indicate that galantamine should be the first choice for treatment of AD, but it must be conceded that the information is less than optimal and differences emerging from meta-analyses of the clinical trials are relatively small. Further comparative experience over the next several years should provide a more definitive assessment of the long-term health and economic consequences of these drugs. Large-scale head-to-head clinical trials between the available cholinesterase inhibitors would provide the evidence base for a more authoritative conclusion on the relative effectiveness and cost-effectiveness of these drugs.

Finally, as new treatments emerge, these will also need to be assessed, even before complete data are available. The AHEAD model provides a framework for these assessments.

None.

Affiliations

1. Caro Research Institute, Concord, MA, 01742, USA
   • Jaime Caro
   •  & Kristen Migliaccio-Walle
2. Division of General Internal Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
   • Jaime Caro
3. Caro Research Institute, Hammonds Plains, Nova Scotia, B4B 1N6, Canada
   • Denis Getsios
4. Caro Research Institute, Dorval, Quebec, H9S 5J9, Canada
   • Jack Ishak
   •  & Wissam El-Hadi

Consortia

Corresponding author

Correspondence to Jaime Caro.

Competing interests

This work was supported in part by a grant from Janssen-Ortho to Caro Research. Janssen-Ortho collaborated in helping set the specifications for the model of this work but had no role in methodological decisions nor interpretation of results. They were also allowed to review and comment on this manuscript but were explicitly forbidden from exerting any editorial control. The authors are employees of Caro Research, and one (JaimeCaro) is a shareholder. Caro Research has also received grants for other, unrelated, research from Pfizer and Novartis, the makers of products potentially affected by this work.

Authors' contributions

All authors contributed substantially to the conception and design of this study, analysis and interpretation, and to the writing of the manuscript. All authors have read and approved the final version of the manuscript.

Reprints and Permissions